GSK3858279

Phase 2Small molecule

GSK

GSK3858279 is one of 60 small molecule programs targeting Neuropathic Pain. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Neuropathic PainActive, not recruiting

OsteoarthritisActive, not recruiting

Neuropathic PainPhase 2

Active, not recruiting

OsteoarthritisPhase 1

Active, not recruiting

Competition

Competitive Landscape

778 competitors in Osteoarthritis

#DrugCompanyPhaseTrials

Ilaris

Novartis

Preclinical

2 2

Voltaren

CCerimon Pharmaceuticals

Preclinical

4 3

Cataflam

Bayer Aspirin

GSK3858279

2 6

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 7

Protonix

WWyeth-Lederle Vaccines

Preclinical

1 8

Catapres

Boehringer Ingelheim

Preclinical

1 9

Benadryl

SGLT2 Inhibitor

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Osteoarthritis2 trials

A Dose-Finding Study to Evaluate the Efficacy and Safety of GSK3858279 in Adults With Knee Osteoarthritis (OA) Pain

Terminated· GSK logo

GSK·Phase 2·NCT05838742·314 enrolled

A Safety, Tolerability, Pharmacokinetics (PK) and Target Engagement (TE) Study of GSK3858279 in Healthy Participants and Evaluation of the Efficacy of Repeat Doses in Participants With Osteoarthritis (OA)

Completed· GSK logo

GSK·Phase 1·NCT03485365·97 enrolled

Neuropathic Pain1 trial

A Study to Evaluate Efficacy and Safety of GSK3858279 in Diabetic Peripheral Neuropathic Pain

Terminated· GSK logo

GSK·Phase 2·NCT05838755·147 enrolled

Tics1 trial

Safety, Tolerability, Pharmacokinetics and Target Engagement of GSK3858279 in Healthy Caucasian, Chinese and Japanese Participants

Completed· GSK logo

GSK·Phase 1·NCT05174013·33 enrolled

Intravenous1 trial

Effects of Intravenous GSK3858279 on a Battery of Evoked Pain Tests in Healthy Volunteers

Terminated· GSK logo

GSK·Phase 1·NCT04114656·21 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for GSK3858279. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GSK3858279 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GSK3858279. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: GSK

GSK3858279

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Osteoarthritis2 trials

Neuropathic Pain1 trial

Tics1 trial

Intravenous1 trial

References

Drug Info

Quick Facts

Related News